2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4058人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995530, encodeId=4b681995530d9, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率, objectType=article, longId=141010, objectId=cb7914101089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7914101089, replyNumber=0, likeNumber=99, createdTime=2019-01-18, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7914101089, moduleTitle=Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb7914101089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995496, encodeId=b6501995496ab, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？, objectType=article, longId=111943, objectId=f4a3111943f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4a3111943f6, replyNumber=0, likeNumber=81, createdTime=2018-06-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4a3111943f6, moduleTitle=Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4a3111943f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995499, encodeId=3ac51995499b3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetologia：SGLT2抑制剂致2型糖尿病患癌症的风险, objectType=article, longId=117295, objectId=f03611e29509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f03611e29509, replyNumber=0, likeNumber=58, createdTime=2018-04-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f03611e29509, moduleTitle=Diabetologia：SGLT2抑制剂致2型糖尿病患癌症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f03611e29509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995534, encodeId=d7bd1995534c1, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？, objectType=article, longId=145809, objectId=5cde145809a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cde145809a9, replyNumber=0, likeNumber=102, createdTime=2019-02-04, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cde145809a9, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cde145809a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995505, encodeId=423c1995505af, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, objectType=article, longId=120735, objectId=9988120e352a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9988120e352a, replyNumber=0, likeNumber=103, createdTime=2018-07-23, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9988120e352a, moduleTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9988120e352a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995520, encodeId=e1ca199552094, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药, objectType=article, longId=133365, objectId=e4531333650d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4531333650d, replyNumber=0, likeNumber=80, createdTime=2018-12-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4531333650d, moduleTitle=Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4531333650d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995506, encodeId=d79d199550662, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Sci Rep：蛋白激酶CK2抑制剂与非小细胞肺癌细胞放射敏感性的关联, objectType=article, longId=121554, objectId=d13a12155458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d13a12155458, replyNumber=0, likeNumber=65, createdTime=2018-06-12, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d13a12155458, moduleTitle=Sci Rep：蛋白激酶CK2抑制剂与非小细胞肺癌细胞放射敏感性的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d13a12155458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995516, encodeId=3acd1995516f5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Angiogenesis：选择性IKK2抑制剂IMD0354抑制角膜炎症和血管生成！, objectType=article, longId=127346, objectId=310712e3460d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310712e3460d, replyNumber=0, likeNumber=53, createdTime=2018-03-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310712e3460d, moduleTitle=Angiogenesis：选择性IKK2抑制剂IMD0354抑制角膜炎症和血管生成！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310712e3460d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995521, encodeId=551d199552126, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=【尖锋档案】P2Y12抑制剂的转换, objectType=article, longId=133590, objectId=c8001335902c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8001335902c, replyNumber=0, likeNumber=71, createdTime=2018-09-08, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8001335902c, moduleTitle=【尖锋档案】P2Y12抑制剂的转换, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8001335902c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995508, encodeId=c6851995508e3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Eur Heart J：非选择性和选择性环氧化酶-2抑制剂是否增加收缩压？, objectType=article, longId=124747, objectId=2a0f124e4737, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a0f124e4737, replyNumber=0, likeNumber=88, createdTime=2018-07-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a0f124e4737, moduleTitle=Eur Heart J：非选择性和选择性环氧化酶-2抑制剂是否增加收缩压？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a0f124e4737)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995504, encodeId=319419955042f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, objectType=article, longId=120661, objectId=dcc912066195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc912066195, replyNumber=0, likeNumber=65, createdTime=2018-08-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc912066195, moduleTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcc912066195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995500, encodeId=24d21995500e7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Pharmacoepidemiol Drug Saf：选择性COX-2抑制剂或传统NSAIDs单独使用或联用PPIs患者的胃肠道毒性, objectType=article, longId=118181, objectId=7381118181a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7381118181a9, replyNumber=0, likeNumber=55, createdTime=2018-08-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7381118181a9, moduleTitle=Pharmacoepidemiol Drug Saf：选择性COX-2抑制剂或传统NSAIDs单独使用或联用PPIs患者的胃肠道毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7381118181a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995517, encodeId=ebba199551e0a, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, objectType=article, longId=129835, objectId=b96412983500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b96412983500, replyNumber=0, likeNumber=66, createdTime=2018-10-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b96412983500, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b96412983500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995522, encodeId=f4dc199552227, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, objectType=article, longId=134756, objectId=8eb0134e56d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eb0134e56d7, replyNumber=0, likeNumber=91, createdTime=2019-01-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eb0134e56d7, moduleTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eb0134e56d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995494, encodeId=e73f199549468, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Care：SGLT2抑制剂服用者发生急性肾损伤的风险分析！, objectType=article, longId=110543, objectId=19a2110543e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a2110543e3, replyNumber=0, likeNumber=76, createdTime=2018-01-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a2110543e3, moduleTitle=Diabetes Care：SGLT2抑制剂服用者发生急性肾损伤的风险分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a2110543e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995512, encodeId=c09c19955127e, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：钠-葡萄糖协同转运体-2抑制剂的短期和中期疗效分析！, objectType=article, longId=126429, objectId=0580126429db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0580126429db, replyNumber=0, likeNumber=75, createdTime=2018-06-09, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0580126429db, moduleTitle=Diabetes Obes Metab：钠-葡萄糖协同转运体-2抑制剂的短期和中期疗效分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0580126429db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995502, encodeId=9f791995502a2, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：服用钠葡萄糖协同转运蛋白2抑制剂的心血管结局和风险！, objectType=article, longId=119974, objectId=414a1199e48b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=414a1199e48b, replyNumber=0, likeNumber=71, createdTime=2018-04-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=414a1199e48b, moduleTitle=Circulation：服用钠葡萄糖协同转运蛋白2抑制剂的心血管结局和风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=414a1199e48b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995503, encodeId=f62d1995503ad, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, objectType=article, longId=120654, objectId=cd061206549f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd061206549f, replyNumber=0, likeNumber=78, createdTime=2018-07-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd061206549f, moduleTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd061206549f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995518, encodeId=225f19955182b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性, objectType=article, longId=130540, objectId=df9e130540b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df9e130540b9, replyNumber=0, likeNumber=103, createdTime=2018-04-26, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df9e130540b9, moduleTitle=Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df9e130540b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995498, encodeId=daef199549834, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet Diabetes Endo：2型糖尿病新用药者SGLT2抑制剂vs其他降糖药的心血管风险, objectType=article, longId=115490, objectId=c0a811549083, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0a811549083, replyNumber=0, likeNumber=67, createdTime=2018-09-22, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0a811549083, moduleTitle=Lancet Diabetes Endo：2型糖尿病新用药者SGLT2抑制剂vs其他降糖药的心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0a811549083)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率

2019-01-18

仁医06 (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？

2018-06-15

仁医06 (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetologia：SGLT2抑制剂致2型糖尿病患癌症的风险

2018-04-03

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？

2019-02-04

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果

2018-07-23

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药

2018-12-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Sci Rep：蛋白激酶CK2抑制剂与非小细胞肺癌细胞放射敏感性的关联

2018-06-12

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Angiogenesis：选择性IKK2抑制剂IMD0354抑制角膜炎症和血管生成！

2018-03-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

【尖锋档案】P2Y12抑制剂的转换

2018-09-08

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Eur Heart J：非选择性和选择性环氧化酶-2抑制剂是否增加收缩压？

2018-07-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微

2018-08-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Pharmacoepidemiol Drug Saf：选择性COX-2抑制剂或传统NSAIDs单独使用或联用PPIs患者的胃肠道毒性

2018-08-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！

2018-10-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好

2019-01-01

仁医06 (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Care：SGLT2抑制剂服用者发生急性肾损伤的风险分析！

2018-01-02

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：钠-葡萄糖协同转运体-2抑制剂的短期和中期疗效分析！

2018-06-09

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：服用钠葡萄糖协同转运蛋白2抑制剂的心血管结局和风险！

2018-04-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？

2018-07-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性

2018-04-26

仁医06 (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet Diabetes Endo：2型糖尿病新用药者SGLT2抑制剂vs其他降糖药的心血管风险

2018-09-22

科室
- - 订阅+
  - 更多科室
工具
服务